On June 11, Kelun-Biotech fell 3.34% in regular trading, trading at HK$388.2/share, with trading volume of approximately HK$50.42 million.

On the sector front, biotech stocks were broadly under pressure, with BeiGene down 2.94%, Akeso down 2.79%, 3SBio down 2.79%, and Innovent Bio down 1.75%, reflecting a systemic pullback in innovative drug assets. For Kelun-Biotech specifically, the company previously reported a widened net loss of RMB 382 million, driven by a sharp decline in licensing and milestone revenue alongside elevated R&D expenditures. Meanwhile, the chairman's continuous share disposals have weighed on short-term market confidence.

Despite multiple brokerages maintaining Buy ratings — with Nomura raising its target price to HK$544.42 — and the company's landmark ASCO data showing a PFS hazard ratio of 0.35 for its core ADC product in PD-L1 positive NSCLC, sector-wide selling pressure has made it difficult for individual stocks to outperform.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)